1995•PubMedRequires access
[A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
D Iu Pushkar', Kosko Dv, O B Loran, Ia D Kan, I M Sapozhnikov, Tevlin Kp
Open publisher page 4 citations
Abstract
94 patients with obstructive urination due to benign prostatic hyperplasia received finasteride (proscar), inhibitor of 5 alpha-reductase, in a single dose 5 mg and terazosine, alpha 1 adrenoblocker, in a daily dose of 9.7 mg/day. The follow-up averaged 16.1 months. As shown by overall score of the symptoms and quality of life, rectal and ultrasonic examinations, uroflowmetry, the prostate decreased by 17%, on the average in 72% of the patients. Subjectively, urination has also improved. Maximal flow rate elevated by 55% in the majority of patients. Combination of finasterine with terazosine is well tolerated and proved optimal as a conservative therapy in patients with obstructive urination as a result of benign prostatic hyperplasia.